Lv3
288 积分 2025-03-26 加入
EZH1/2 Dual Inhibitor Valemetostat Tosylate (DS-3201b) Acts Differently from EZH2 Selective Inhibitor on Epigenetic Landscape to Exert Greater Anti-Tumor Effect Against Diffuse Large B-Cell Lymphoma
17天前
已完结
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
21天前
已完结
IMMUNE THROMBOCYTOPENİA: PATHOPHYSIOLOGY AND MOLECULAR BIOLOGY
21天前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
2个月前
已完结
EZH1/2 Dual Inhibitor Valemetostat Tosylate (DS-3201b) Acts Differently from EZH2 Selective Inhibitor on Epigenetic Landscape to Exert Greater Anti-Tumor Effect Against Diffuse Large B-Cell Lymphoma
2个月前
已完结
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
2个月前
已完结
Janus Kinase (Jak) 1 Inhibition Affects Both Megakaryopoiesis and Thrombopoiesis
2个月前
已完结
Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside
2个月前
已完结
PCSK9 inhibitors: clinical evidence and implementation
3个月前
已完结
Molecular basis of PCSK9 function
3个月前
已完结
皖公网安备34019202002308
